Riva Spar 9mg Patch 30’s

Riva Spar 9mg Patch contains Rivastigmine, a medication used in the management of mild to moderate Alzheimer’s disease and Parkinson’s disease dementia. The transdermal patch delivers a continuous release of Rivastigmine through the skin, allowing for stable therapeutic levels and improving patient compliance compared to oral administration. This patch helps enhance cognitive function, daily living activities, and overall quality of life for individuals suffering from these neurodegenerative disorders. The patch is easy to apply and remove, making it a convenient option for long-term treatment.

Uses:

• Treatment of mild to moderate Alzheimer’s disease
• Management of dementia associated with Parkinson’s disease

Side Effects:

• Common side effects include nausea, vomiting, diarrhea, and abdominal pain.
• Serious side effects may include skin reactions, bradycardia (slow heart rate), and gastrointestinal bleeding. Consult a healthcare provider for any unusual symptoms.

Key Features:

• Delivers a consistent dose of Rivastigmine over 24 hours
• Easy-to-apply transdermal patch
• Helps improve cognitive function and daily living activities

FAQ:

1. What is Riva Spar Patch used for?
   • Riva Spar Patch is used for treating mild to moderate Alzheimer’s disease and dementia associated with Parkinson’s disease.
2. How do I apply the Riva Spar Patch?
   • Clean and dry the application area, remove the patch from its packaging, and apply it to a flat area of skin, avoiding any broken or irritated skin.
3. What should I do if I miss a dose?
   • If you miss a dose, apply the patch as soon as you remember. If it’s almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not apply two patches at once.
4. Can Riva Spar Patch cause side effects?
   • Yes, common side effects may include nausea and vomiting, while more serious side effects can occur. Consult your healthcare provider if you experience any severe reactions.

References:

• European Medicines Agency. (2020). “Rivastigmine transdermal patch.” [Accessed on 5th May 2023]. Available from: https://www.ema.europa.eu/en/documents/product-information/exelon-epar-product-information_en.pdf
• National Institutes of Health. (2021). “Rivastigmine transdermal system.” [Accessed on 5th May 2023]. Available from: https://medlineplus.gov/druginfo/meds/a699059.html